OUR STORY

The World Orphan Drug Congress is an award-winning event with an exhibition that has grown to become the largest and most established orphan drugs & rare diseases meeting of its kind across the globe. Our credibility is shown through the prestigious advisory board that spend months of hard work creating a new and topical agenda, year on year.

Now in its 14th annual, the World Orphan Drug Congress Europe will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering.

With 1000+ of potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the OMP legislation review and EUHTA as well as commercial and scientific issues in evidence generation, regulation, clinical trials, market access, pricing, manufacturing, gene therapy and precision medicine.

This one event will provide you with a one stop progressive scientific and strategic solution to the orphan drugs industry. Now recognised as the largest and most established multi-stakeholder rare disease meeting, we are once again proud to deliver another outstanding speaker line-up and a content-filled agenda that represents the whole orphan drug landscape.

We’ve integrated the patient voice directly into every part of the agenda, reflected in in their attendance to our congress year on year, and through our strategic partnerships with EURORDIS, NORD, RDI, Findacure, FEDER, CIBER-ER & many more.

Be part of our best year yet.

Conference Themes

Cell & Gene Therapies

Genetic Testing

Gene Editing

Partnering & Investment

Global Market Access

Expanded Access Programs

Real World Evidence

Global Patient Advocacy

Value Based Pricing & Reimbursement

Epidemiology & Forecasting

Orphan Drugs Policy

Gene Therapy Development

Clinical Trials

Payers, HTA and Pricing

Manufacture

WORLD ORPHAN DRUG CONGRESS IS ALL ABOUT OPPORTUNITY

Contact Michael now at michael.hodge@terrapinn.com to secure your place

WORLD ORPHAN DRUG CONGRESS

WHY NOW?

ORPHAN REGULATION & POLICY

The regulatory authorities and European Commission couldn’t stress enough the importance of early dialogue and common assessment. Coupled with the European Commission’s proposal to change the orphan legislation, every stakeholder involved in orphan drugs will be impacted. Come to this congress to understand how to adapt to these new changes, gain scientific advice, a pathway to help secure accelerated approval and early consultation. Only in-person can you get real feedback and alignment between regulators, HTA and drug developers.

PRICING, REIMBURSEMENT & ACCESS IS COMPLEX IN EUROPE

Pricing and access to medicines is a very challenging and complex journey, and even more so when we consider new, innovative gene therapies and rare orphan drugs. That’s why the WODC has dedicated 4 days of content on addressing these issues. This includes value evidence and perspectives from industry and patients, feedback from HTAs and payers on commercial negotiations to large European initiatives and health ministers to gain better insights on its sustainability.

THE NEED FOR TRUE COLLABORATION

The rare disease community is crying out for new models to run natural history studies, registries, European Reference Networks, sustainable real-world evidence, meaningful clinical endpoints to name a few, are you inclusive in your strategy? The WODC is unique in the way we bring together all stakeholders, including patients to help challenge new partnerships and collaborations.

GENE THERAPIES

With the recent landmark EU approvals for one-time gene therapies, it’s imperative that as an industry we discuss and find solutions persisting questions around appropriate reimbursement models, patient access and scale up challenges.

PRECISION MEDICINE

How will the impact of new digital and computational tools affect rare disease diagnostics and patient care? Learn how genomics, sequencing and AI are changing the way patients access diagnostics and treatments. As we get all these precision medicine tools on our fingertips, treatments should become more and more accessible, find out how.

“It's an excellent opportunity to be updated on the most relevant issues for OD and interact with people working in the field.”

- Director Therapeutic Expertise, Rare Disease Laboratorios Biopas

“The program was well balanced and provided many opportunities for exchange on some of the most burning themes.”

- Senior Director Government Relations, Orchard Therapeutics

“Good and relevant topics, smooth organisation of the event, excellent environment to meet peers and stakeholders“

- Head of Government Affairs and Public Policy EMEA & APAC, PTC Therapeutics